Vanoglipel

Vanoglipel
Clinical data
Other namesDA-1241; DA1241
Drug classGPR119 agonist
Identifiers
  • 3-[4-[3-[1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,2,4-oxadiazole
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC25H31F2N5O2
Molar mass471.553 g·mol−1
3D model (JSmol)
  • CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(=N3)C(C)C)C(F)=C2)CC1
  • InChI=1S/C25H31F2N5O2/c1-4-17-14-28-25(29-15-17)32-9-7-18(8-10-32)6-5-11-33-19-12-20(26)22(21(27)13-19)23-30-24(16(2)3)34-31-23/h12-16,18H,4-11H2,1-3H3
  • Key:XQSZLXRXPGLHLH-UHFFFAOYSA-N

Vanoglipel (INNTooltip International Nonproprietary Name), also known by its developmental code name DA-1241, is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes. As of August 2026, it is in phase 2 clinical trials for non-alcoholic steatohepatitis and phase 1 trials for type 2 diabetes.

See also

References

  1. 1 2 "Vanoglipel - Dong-A ST". adisinsight.springer.com. Retrieved 28 October 2026.
  2. ↑ Lee, Seung-Ho; Park, Hansu; Yang, Eun-Kyoung; Lee, Bo Ram; Jung, Il-Hoon; Kim, Tae-Hyoung; Goo, Moon Jung; Chae, Yuna; Kim, Mi-Kyung (October 2023). "GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling". Biomedicine & Pharmacotherapy. 166 115345. doi:10.1016/j.biopha.2023.115345. PMID 37657264.
  3. ↑ Kim, Mi-Kyung; Cheong, Ye Hwang; Lee, Seung Ho; Kim, Tae Hyoung; Jung, Il Hoon; Chae, Yuna; Lee, Jeong-Ha; Yang, Eun Kyoung; Park, Hansu; Yang, Jae-Sung; Hong, Ki Whan (December 2021). "A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression". Biomedicine & Pharmacotherapy. 144 112324. doi:10.1016/j.biopha.2021.112324. PMID 34678732.
  4. ↑ Kim, Mi-Kyung; Lee, Dae Young; Jeong, Jiyoon; Grimm, Michael; Franey, Bridgette B.; Hompesch, Marcus (1 June 2021). "766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)". Diabetes. 70 (Supplement_1) 766-P. doi:10.2337/db21-766-P. S2CID 237883271.
  5. ↑ Kim, Youjin; Lee, Si Woo; Wang, Hyejin; Kim, Ryeong-Hyeon; Park, Hyun Ki; Lee, Hangkyu; Kang, Eun Seok (31 March 2022). "DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice". Diabetes & Metabolism Journal. 46 (2): 337–348. doi:10.4093/dmj.2021.0056. PMC 8987681. PMID 35052026.